KRAS and colorectal carcinoma: Since K-ras mutations are especially prevalent in colorectal carcinoma (40–45% of cases) and non-small cell lung cancer (NSCLC) (16–40%), our study suggests that testing for K-ras mutations could be very important for patient selection in the future clinical trials of SAHA treatment.